Connor Clark & Lunn Investment Management Ltd. Boosts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Connor Clark & Lunn Investment Management Ltd. grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 32.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,532 shares of the biotechnology company’s stock after purchasing an additional 3,573 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in United Therapeutics were worth $5,127,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Milestone Asset Management LLC increased its holdings in shares of United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 1,037 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of United Therapeutics by 9.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock valued at $3,326,000 after purchasing an additional 789 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of United Therapeutics by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock valued at $68,999,000 after purchasing an additional 50,291 shares in the last quarter. Burney Co. increased its holdings in shares of United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock valued at $8,441,000 after purchasing an additional 12,705 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Up 0.6 %

Shares of UTHR opened at $307.24 on Monday. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82. The firm’s fifty day moving average is $349.77 and its two-hundred day moving average is $358.53. The stock has a market cap of $13.80 billion, a PE ratio of 13.49, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the previous year, the company posted $4.36 EPS. As a group, research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group boosted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

Insider Activity

In other news, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the transaction, the director now owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 116,464 shares of company stock valued at $42,396,244. 11.90% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.